Hans Gelderblom, MD, PhD, discusses the correlation between the overall response rate by Tumor Volume Score and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.
Hans Gelderblom, MD, PhD, professor of medical oncology at Leiden University Medical Centre, discusses the correlation between the overall response rate by Tumor Volume Score (TVS) and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.
In the phase III ENLIVEN trial, there was a 39% response rate by RECIST criteria in patients randomized to pexidartinib. However, these patients also had a 56% response rate by TVS criteria, says Gelderblom.
In Real-World Analyses, Apalutamide Delivers Quicker Responses in Prostate Cancer
June 15th 2024Benjamin Lowentritt, MD, discussed findings from real-world analyses looking at enzalutamide or abiraterone vs apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More